Alliance acquires Novartis's obstetric drug
This article was originally published in Scrip
Executive Summary
UK-based specialty company Alliance Pharma has acquired all rights to Novartis' obstetrics drug, Syntometrine (oxytocin/ergometrine) for $11.5m.